Navigation Links
CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
Date:1/6/2017

LA JOLLA, Calif., Jan. 6, 2017 /PRNewswire/ -- Privately-held CalciMedica, Inc., announced that it started Phase 1 safety studies in healthy volunteers of a novel calcium release-activated calcium (CRAC) channel inhibitor, CM4620, intended to treat acute pancreatitis.

Acute pancreatitis, sudden painful inflammation of the pancreas, is typically a mild disorder, but can be very serious.  In severe cases it can lead to organ failure and sepsis, where extended hospital stays, time in the ICU and substantial morbidity and even mortality are seen. Acute pancreatitis has many different causes, ranging from alcohol and gall stones, which are responsible for the majority of cases, to drug reactions, viral infections or local cancers; there are also hereditary forms.  At this time there are no disease-modifying therapies available; patients receive supportive care, including fluids and pain medication.

Michael Dunn, President of CalciMedica, said, "We are very excited that CM4620 has advanced to human studies.  Acute pancreatitis is a disease with significant unmet medical need, especially its more severe form.  Our preclinical work and that of others strongly indicates that excess calcium in pancreatic cells is a key player in this disease.  We believe that CM4620 can help to modify the disease process and benefit patients, and hope to progress from these safety studies to testing in patients by the end of this year."

About CRAC channels and Orai

CRAC channels, comprising Orai and regulatory STIM proteins, function to maintain proper levels of calcium in most non-excitable cells.  In immune cells, particularly T cells, calcium is an important intracellular signaling molecule that controls cytokine production and the immune response.  In T cells CRAC channels are the primary means by which intracellular calcium levels are modulated.  In addition, aberrant activation of CRAC channels in pancreatic acinar cells is thought to play a key role in the pathobiology of acute pancreatitis.

About CalciMedica, Inc.

CalciMedica is the leading biopharmaceutical company focused on CRAC channel drug discovery and development, seeking novel drugs for the treatment of acute or chronic diseases in which inflammation plays a role. For example, CRAC channels control calcium entry that is essential for the adaptive immune response, and this pathway has been clinically validated as an important drug target in humans through the use of calcineurin inhibitors that act downstream from CRAC channels. For more information, please visit the company website at www.calcimedica.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/calcimedica-initiates-phase-1-clinical-studies-for-crac-channel-inhibitor-300386948.html


'/>"/>
SOURCE CalciMedica, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform
2. China National Genebank initiates collaboration to sequence transcriptomes of 1,000 fish species
3. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
4. Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism
5. NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer
6. Rolapitant reduces nausea and vomiting in Phase III trial
7. NIH funds next phase of Tissue Chip for Drug Screening program
8. Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN
9. New simple setup for X-ray phase contrast
10. More than just a hill of beans: Phaseolus genome lends insights into nitrogen fixation
11. ASU embarks on $9 million next phase of an effort to assess an absorbed radiation dose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):
(Date:5/24/2017)... ... May 24, 2017 , ... ... implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery (ABNR™) technology at its ... a $24 million plant upgrade to sustainably meet current and future nutrient discharge ...
(Date:5/24/2017)... ... May 24, 2017 , ... Patient ... developed with Wi-Fi connectivity to reduce the amount of wiring in a healthcare ... addition, compact mobile devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, ...
(Date:5/23/2017)... Westminster, Colorado (PRWEB) , ... May 23, 2017 , ... ... amaranth as the most troublesome and difficult to control weed in 12 categories of ... found. , Almost 200 weed scientists across the U.S. and Canada participated in the ...
(Date:5/23/2017)... ... May 22, 2017 , ... ... row in the Aragon Research Globe™ for Corporate Learning, 2017. , Aragon Research ... and market demand, and effectively perform against those strategies. NetDimensions’ ranking as a ...
Breaking Biology Technology: